Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets

Pharmacogenetics and Genomics

Volumn 15, Issue 8, 2005, Pages 579-587

  Kirchheiner, Julia ^a,b   Henckel, Harms Benjamin ^a   Franke, Leonora ^a   Meineke, Ingolf ^c   Tzvetkov, Mladen ^c   Uebelhack, Ralf ^a   Roots, Ivar ^a   Brockmöller, Jürgen ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Antidepressants; CYP2D6; Doxepin; Pharmacogenetics; Ultra rapid metabolizer

Indexed keywords

5 METHOXYTRYPTAMINE; CYTOCHROME P450 2D6; DOXEPIN; NORDOXEPIN; SEROTONIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; GENE DUPLICATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEDATION; SEROTONIN UPTAKE; SINGLE NUCLEOTIDE POLYMORPHISM; STEREOCHEMISTRY; THROMBOCYTE;

EID: 22944482153     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000167331.30905.9e     Document Type: Article

References (41)

1. Bogaert MG, Rosseel MT, Deberdt R, Vranckx C. Plasma levels of the cis- and trans-isomers of doxepin and desmethyldoxepin after administration of doxepin to patients. Arzneimittelforschung 1981; 31:113-115.
2. Hrdina PD, Bakish D, Swenson S, Lapierre YD. Cis- and trans-isomers of doxepin and desmethyldoxepin in the plasma of depressed patients treated with doxepin. Ther Drug Monit 1990; 12:129-133.
3. Deuschle M, Hartter S, Hiemke C, Standhardt H, Heuser I. Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients. Psychopharmacology (Berl) 1997; 131:19-22.
4. Adamczyk M, Fishpaugh JR, Harrington C. Quantitative determination of E- and Z-doxepin and E- and Z-desmethyldoxepin by high-performance liquid chromatography. Ther Drug Monit 1995; 17:371-376.
5. Midha KK, Hubbard JW, McKay G, Hawes EM, Korchinski ED, Gurnsey T, et al. Stereoselective pharmacokinetics of doxepin isomers. Eur J Clin Pharmacol 1992; 42:539-544.
6. Schaumann W, Ribbentrop A. Interference of the central anticholinergic effect in experimental animal tests of potential antidepressives. Arzneimittelforschung 1966; 16:646-649.
7. Ribbentrop A, Schaumann W. Pharmacologic studies of doxepin, an antidepressive agent with centrally anticholinergic and sedative effects. Arzneimittelforschung 1965; 15:863-868.
8. Otsuki I, Ishikawa J, Sakai M, Shimabara K, Momiyama T. Comparison of the pharmacological activities of doxepin hydrochloride with those of its geometric isomers. Pharmacometrics (Tokyo) 1972; 6:973-984.
9. Faulkner RD, Pitts WM, Lee CS, Lewis WA, Fann WE. Multiple-dose doxepin kinetics in depressed patients. Clin Pharmacol Ther 1983; 34: 509-515.
10. Ward NG, Bloom VL, Wilson L, Raskind M, Raisys VA. Doxepin plasma levels and therapeutic response in depression: preliminary findings. J Clin Psychopharmacol 1982; 2:126-128.
11. Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W. Doxepin plasma concentrations: is there really a therapeutic range? J Clin Psychopharmacol 2001; 21:432-439.
12. Haritos V, Ghabrial H, Ahokas J, Ching M. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics 2000; 10:591-603.
13. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12:571-580.
14. Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004; 59:803-807.
15. Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin Pharmacol Ther 2004; 75:386-393.
16. Jamnicky B, Muck-Seler D, Deanovic Z. Effect of doxepin on serotonin metabolism in rat brain and serotonin uptake by human blood platelets. Prog Neuropsychopharmacol 1980; 4:253-260.
17. Franke L, Schewe HJ, Uebelhack R, Muller-Oerlinghausen B. High platelet-serotonin uptake activity is associated with a rapid response in depressed patients treated with amitriptyline. Neurosci Lett 2003; 345:105-108.
18. Bianchi M, Moser C, Lazzarini C, Vecchiato E, Crespi F. Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes. Exp Brain Res 2002; 143:191-197.
19. Karege F, Widmer J, Bovier P, Gaillard JM. Platelet serotonin and plasma tryptophan in depressed patients: effect of drug treatment and clinical outcome. Neuropsychopharmacology 1994; 10:207-214.
20. Muck-Seler D, Pivac N, Mustapic M, Crncevic Z, Jakovljevic M, Sagud M, et al Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Res 2004; 127:217-226.
21. Perez V, Bel N, Celada P, Ortiz J, Alvarez E, Artigas F. Relationship between blood serotonergic variables, melancholic traits, and response to antidepressant treatments. J Clin Psychopharmacol 1998; 18:222-230.
22. Figueras G, Perez V, San Martino O, Alvarez E, Artigas F. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de Trastornos Afectivos. Biol Psychiatry 1999; 46:518-524.
23. Ross SB, Aperia B, Beck-Friis J, Jansa S, Wetterberg L, Aberg A. Inhibition of 5-hydroxytryptamine uptake in human platelets by antidepressant agents in vivo. Psychopharmacology (Berl) 1980; 67:1-7.
24. Martensson B, Wagner A, Beck O, Brodin K, Montera D, Asberg M. Effects of clomipramine treatment on cerebrospinal fluid monoamine metabolites and platelet 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder. Acta Psychiatr Scand 1991; 83:125-133.
25. Stain-Malmgren R, Khoury AE, Aberg-Wistedt A, Tham A. Serotonergic function in major depression and effect of sertraline and paroxetine treatment. Int Clin Psychopharmacol 2001; 16:93-101.
26. Rausch JL, Corley KM, Hobby HM. Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique. J Clin Psychopharmacol 2004; 24:209-213.
27. Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 2004; 36:243-277.
28. Eichelbaum M. In search of endogenous CYP2D6 substrates. Pharmacogenetics 2003; 13:305-306.
29. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13:173-181.
30. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology 1973; 10:431-436.
31. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
32. Raimundo S, Fischer J, Eichelbaum M, Griese E, Schwab M, Zanger U. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10:577-581.
33. Fuselli S, Dupanloup I, Frigato E, Cruciani F, Scozzari R, Moral P, et al. Molecular diversity at the CYP2D6 locus in the Mediterranean region. Eur J Hum Genet 2004; 12:916-924.
34. Kaiser R, Tremblay PB, Schmider J, Henneken M, Dettling M, Muller-Oerlinghausen B, et al. Serotonin transporter polymorphisms: no association with response to antipsychotic treatment but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol Psychiatry 2001; 6:179-185.
35. Franke L, Schewe HJ, Muller B, Campman V, Kitzrow W, Uebelhack R, et al. Serotonergic platelet variables in unmedicated patients suffering from major depression and healthy subjects: relationship between 5HT content and 5HT uptake. Life Sci 2000; 67:301-305.
36. Pinder RM, Brogden RN, Speight TM, Avery GS. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 1977; 13:161-218.
37. Muller MJ, Dragicevic A, Fric M, Gaertner I, Grasmader K, Hartter S, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry 2003; 36: 98-104.
38. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104:173-192.
39. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004; 50:1623-1633.
40. Rao ML, Frahnert C, Zagorski O. Initial serotonin transport into viable platelets and imipramine binding to platelet membranes. J Neural Transm 2002; 109:547-556.
41. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91:119-128.